May 20, 2026 06:03AM Belite Bio (BLTE) Tops Q1 EPS by 30c

May 18, 2026 04:00PM Belite Bio receives orphan drug status in Switzerland for retinal therapy

Apr 21, 2026 04:00PM Belite Bio begins FDA rolling submission for Stargardt disease treatment

Apr 13, 2026 06:38AM H.C. Wainwright Reiterates Buy Rating on Belite Bio, Inc, ADR (BLTE)

Apr 13, 2026 05:52AM Bernstein on US Pharma and Biotech: Who might buy whom?

Apr 7, 2026 07:46AM Belite Bio ADR (BLTE) Reiterated at Buy by Benchmark After Model Update

Mar 4, 2026 08:42AM Mizuho Reiterates Outperform Rating on Belite Bio, Inc, ADR (BLTE): "very well positioned"

Mar 4, 2026 06:42AM Belite Bio, Inc, ADR (BLTE) PT Raised to $200 at H.C. Wainwright

Mar 3, 2026 09:37AM Belite Bio, Inc, ADR (BLTE) PT Raised to $217 at Benchmark Following Business Update

Mar 3, 2026 07:44AM Belite Bio, Inc, ADR (BLTE) PT Raised to $266 at Cantor Fitzgerald After Higher WAC Announced

Mar 2, 2026 04:27PM Belite Bio (BLTE) Tops Q4 EPS by 15c

Jan 28, 2026 06:43AM H.C. Wainwright Reiterates Buy Rating on Belite Bio, Inc, ADR (BLTE)

Jan 27, 2026 08:04AM Belite Bio completes enrollment in DRAGON II trial for Stargardt disease

Jan 26, 2026 06:12AM BofA Securities Starts Belite Bio, Inc, ADR (BLTE) at Buy

Jan 16, 2026 07:08AM Belite Bio (BLTE) Reiterated at Overweight by Cantor Fitzgerald

Jan 6, 2026 02:10AM Morgan Stanley Starts Belite Bio, Inc, ADR (BLTE) at Overweight

Dec 3, 2025 08:44AM Belite Bio, Inc, ADR (BLTE) PT Raised to $187 at Benchmark on Positive Phase 3 Dragon Trial Results

Dec 2, 2025 05:06AM Mizuho Upgrades Belite Bio, Inc, ADR (BLTE) to Outperform

Nov 24, 2025 06:12AM Cantor Fitzgerald Assumes Belite Bio, Inc, ADR (BLTE) at Overweight

Nov 20, 2025 05:36AM Mizuho Starts Belite Bio, Inc, ADR (BLTE) at Neutral

Nov 11, 2025 03:51PM Belite Bio, Inc, ADR (BLTE) PT Raised to $140 at Maxim Group

Nov 10, 2025 05:11PM Belite Bio (BLTE) Tops Q3 EPS by 22c

Nov 3, 2025 03:52AM Belite Bio receives UK regulatory nod for Stargardt disease drug application

Oct 17, 2025 06:46AM H.C. Wainwright Reiterates Buy Rating on Belite Bio, Inc, ADR (BLTE)

Oct 15, 2025 08:02AM Belite Bio receives China NMPA priority review for Stargardt treatment

Sep 15, 2025 07:28AM Belite Bio, Inc, ADR (BLTE) PT Lowered to $98 at H.C. Wainwright

Sep 10, 2025 08:51AM Benchmark Reiterates Buy Rating on Belite Bio, Inc, ADR (BLTE) Following PIPE Transaction

Aug 12, 2025 09:42AM Benchmark Reiterates Buy Rating on Belite Bio, Inc, ADR (BLTE)

Aug 11, 2025 06:32AM Belite Bio (BLTE) Tops Q2 EPS by 8c

Jul 3, 2025 06:46AM H.C. Wainwright Reiterates Buy Rating on Belite Bio, Inc, ADR (BLTE)

May 22, 2025 08:39AM Benchmark Reiterates Buy Rating on Belite Bio, Inc, ADR (BLTE)

May 15, 2025 09:10AM Benchmark Reiterates Buy Rating on Belite Bio, Inc, ADR (BLTE)

May 15, 2025 07:23AM Cantor Fitzgerald Reiterates Overweight Rating on Belite Bio, Inc, ADR (BLTE)

May 14, 2025 04:52PM Belite Bio (BLTE) Tops Q1 EPS by 10c

Mar 26, 2025 08:39AM Belite Bio, Inc, ADR (BLTE) PT Raised to $80 at Benchmark

Mar 18, 2025 06:41AM H.C. Wainwright Reiterates Buy Rating on Belite Bio, Inc, ADR (BLTE)

Mar 17, 2025 07:06AM Cantor Fitzgerald says 15% of biotech companies down 40% or more

Mar 17, 2025 06:06AM Belite Bio (BLTE) Reports In-Line Q4 EPS

Jan 21, 2025 06:49AM Belite Bio, Inc, ADR (BLTE) PT Raised to $79 at Benchmark

Nov 13, 2024 06:52AM Belite Bio, Inc, ADR (BLTE) PT Raised to $100 at H.C. Wainwright

Nov 12, 2024 04:06PM Belite Bio (BLTE) Tops Q3 EPS by 1c

Sep 12, 2024 07:49AM H.C. Wainwright Reiterates Buy Rating on Belite Bio, Inc, ADR (BLTE)

Aug 13, 2024 04:41PM Belite Bio (BLTE) Misses Q2 EPS by 26c

Aug 13, 2024 06:43AM Belite Bio, Inc, ADR (BLTE) PT Raised to $60 at H.C. Wainwright

Aug 12, 2024 03:41AM Belite Bio, Inc (BLTE) Misses Q1 EPS by 5c